Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
With
Merck Serono Limited, UK
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Physician diagnosis of HDA-RRMS as defined by clinical or radiological features
Treatment initiation with cladribine tablet monotherapy on or after 22 August 2017 and at least 3 years before enrolment
Completion of Year 1 treatment of cladribine tablets (Week 1 and Week 2 treatment, per recommended dose in Year 1: 1.75 milligrams per kilogram \[mg/kg\] body weight, cumulatively)
You may not be if
Received cladribine tablet treatment within an interventional clinical trial during the study period
Received treatment with any investigational therapy for RRMS in the 6 months prior to cladribine tablet treatment initiation
